Application of liver-soothing and qi-guiding composition in preparation of anti-anxiety drugs

Through the specific formula and preparation method of Shugan Shunqi composition, the problem of the development of Shugan Shunqi Pills and the lack of anti-anxiety drugs is solved, and effective treatment of functional indigestion with anxiety symptoms is achieved, which improves anti-anxiety and Antidepressant efficacy.

CN119033893AActive Publication Date: 2024-11-29CHONGQING HILAN PHARM CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202411032660.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-29
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

The use and indications of Shugan Shunqi Pills in the prior art need to be further developed, and effective anti-anxiety Chinese patent medicines are lacking in clinical practice.

Method used

Compositions made of a combination of soothing liver and shunqi using a specific proportion of medicinal materials, including Magnolia officinalis, Chuanxiong, Xiangfu, Baishao, Bupleurum, Citrus aurantium, Tulipa, Buddha's hand, Muxiang, Tangerine peel, licorice and Malancao is prepared into pills, granules, tablets, etc. by crushing, distillation and extraction, decoction and extraction, etc., and controls pH value and inclusion treatment to improve the efficacy of the medicine.

Benefits of technology

Significantly improves the symptoms of functional indigestion with anti-anxiety, improves the therapeutic effect of anti-anxiety and anti-depression, and enhances the efficacy and safety of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention relates to the technical field of anxiety disorder treatment medicines, in particular to application of a liver-soothing and qi-guiding composition in preparation of an anti-anxiety medicine. The liver-soothing and qi-guiding composition has the major functions of soothing the liver, regulating qi and relieving pain; the traditional Chinese medicine is used for liver depression and qi stagnation syndromes, including fullness of two hypochondrium, stabbing pain in epigastric cavity, vomiting, noisy vomiting, belching and acid regurgitation. Clinical tests find that in addition to the application, the liver-soothing and qi-guiding composition can also be used for treating anxiety disorder, and especially has an ideal treatment effect on dyspepsia accompanied by anxiety (liver depression and qi stagnation syndrome). Besides, according to the technical scheme, improvement is carried out on the basis of an original liver-soothing and qi-guiding pill, the dissolution degree of functional components is improved in an extraction mode, and the problems that the number of medicine using people is limited and the medicine taking compliance of patients is poor are solved by preparing multiple dosage forms and avoiding the mode of adding honey. And the preparation method and the dosage form are improved, so that the effect of treating the anxiety disorder by the medicine is further improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of drugs for treating anxiety disorders, and in particular to use of a liver-soothing and qi-smoothing composition in the preparation of antianxiety drugs. Background Art

[0002] Anxiety disorder is a common psychological disorder characterized by persistent, excessive, and uncontrollable feelings of worry and fear that are disproportionate or irrelevant to the actual situation. People with anxiety disorders often have excessive worries about trivial things in daily life or things that may happen in the future. The diagnosis of anxiety disorders is usually based on the criteria listed in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), and different types of anxiety disorders have different diagnostic indicators. The treatment of anxiety disorders usually includes two main approaches: medication and psychotherapy, and sometimes it is combined with lifestyle adjustments and auxiliary treatments. In the clinical prevention and treatment of anxiety disorders, traditional Chinese medicine is relatively slow in onset, mild in efficacy, has fewer adverse reactions, and has good long-term treatment efficacy. Traditional Chinese medicine regimens for the treatment of anxiety disorders are usually based on traditional Chinese medicine theory and are formulated for the specific symptoms and constitution of individuals. Traditional Chinese medicine believes that anxiety disorders may be caused by a variety of "syndromes", such as liver qi stagnation, heart and spleen deficiency, and heart and kidney disharmony. Therefore, the treatment plan will select the appropriate drug combination based on the principle of syndrome differentiation and treatment. For example, Guipi Decoction, which is made up of angelica, white atractylodes, longan meat, and fried jujube seeds, is suitable for anxiety symptoms caused by deficiency of both the heart and spleen.

[0003] Shugan Shunqi Pills are a pure Chinese medicine preparation made by adding and subtracting the optimized version of Chaihu Shugan Powder in Jingyue Complete Works. It is composed of 13 Chinese medicines, including Bupleurum, Cyperus (vinegar-processed), White Peony Root, Curcuma, Fructus Aurantii Immaturus (fried), Magnolia Officinalis, Aucklandia Rhizoma, Citrus Palmatum, Corydalis (vinegar-fried), Ligusticum chuanxiong, Amaranthus, Tangerine Peel, and Licorice. Shugan Shunqi Pills (National Medicine Standard Z20026802, Standard Number: WS-11169 (ZD-1169)-2002-2011Z) are large black honey pills, each weighing about 9g. Its functions and indications are: soothing the liver, regulating qi, and relieving pain. It is used for the symptoms of liver depression and qi stagnation, with symptoms of: fullness in the flanks, stabbing pain in the stomach, vomiting and nausea, belching and acid reflux. Experimental studies have shown that Shugan Shunqi Pills can effectively improve the symptoms of functional dyspepsia model and gastrointestinal motility disorder model, inhibit gastric acid secretion, promote gastrointestinal motility, improve serum gastrointestinal hormone levels, increase pepsin activity, and also have obvious pharmacological effects of increasing intestinal absorption and analgesia.

[0004] In addition to the above-mentioned therapeutic effects, some literature points out that Shugan Shunqi Pills also have the following therapeutic effects: Shugan Shunqi Pills can dissolve cholesterol stones and bile pigment stones, inhibit the formation of new stones, and promote the appearance of high-amplitude interval peak potentials to varying degrees, suggesting that Shugan Shunqi Pills may have a good therapeutic effect on liver dysfunction and yang juice dysfunction (Chen Li, Lv Shanshan, Qiao Zhiwen, et al. Study on the choleretic pharmacodynamics of Shugan Shunqi Pills [J]. World Journal of Integrated Traditional and Western Medicine, 2014, 9(12): 1281-1284.). Shugan Shunqi Pills have a strong effect in improving the symptoms of functional dyspepsia and treating gastric ulcers (Lv Shanshan, Zhounianhua, Yang Hui, et al. Protective effect of Shugan Shunqi Pills on gastric ulcer and reflux esophagitis model mice [J]. Chinese Pharmacy, 2014, 25(23): 2121-2124.). Shugan Shunqi Pills have good anti-inflammatory effects and can significantly improve pathological changes such as swelling and hyperplasia caused by inflammation. They have a certain effect on the treatment of superficial gastritis and other digestive tract inflammations (Qiao Zhiwen, Chen Li, Lv Shanshan, et al. Study on the anti-inflammatory effect of Shugan Shunqi Pills [J]. Chinese Pharmacy, 2013, 24 (47): 4444-4446.). Therefore, the therapeutic use of Shugan Shunqi composition needs to be further explored to enrich the selection of anti-anxiety drugs in clinical practice. Summary of the invention

[0005] The present invention is intended to provide an application of a Shugan Shunqi composition in the preparation of antianxiety drugs, so as to solve the technical problems that the uses and indications of the Shugan Shunqi pills in the prior art need to be further developed and there is a lack of effective anti-anxiety Chinese patent medicines in clinical practice.

[0006] In order to achieve the above object, the present invention adopts the following technical scheme:

[0007] Application of a soothing and relieving qi composition in the preparation of an anti-anxiety drug, the soothing and relieving qi composition being prepared from the following medicinal raw materials in parts by weight: 25-35 parts of Magnolia officinalis, 25-35 parts of Chuanxiong, 25-35 parts of Cyperus rotundus, 25-35 parts of White Peony Root, 25-35 parts of Bupleurum Root, 25-35 parts of Citrus aurantium, 25-35 parts of Curcuma aromatica, 25-35 parts of Citrus citron, 25-35 parts of Aucklandia lappa, 25-35 parts of Tangerine peel, 20-30 parts of Licorice, 25-35 parts of Corydalis yanhusuo and 45-60 parts of Amaranthus chinensis;

[0008] Preferably, the liver-soothing and qi-relief composition is made of the following medicinal raw materials in the following parts by mass: 31.4 parts of Magnolia officinalis, 31.4 parts of Chuanxiong, 31.4 parts of Cyperus rotundus, 31.4 parts of White Peony Root, 31.4 parts of Bupleurum Root, 31.4 parts of Citrus aurantium, 31.4 parts of Curcuma aromatica, 31.4 parts of Citrus citrus hand, 31.4 parts of Aucklandia lappa, 31.4 parts of Tangerine peel, 23.55 parts of Licorice, 31.4 parts of Corydalis yanhusuo and 58.85 parts of Amaranthus grandiflora.

[0009] The present technical scheme also provides an application of a soothing and relieving qi composition in the preparation of a drug for improving, assisting in the treatment or treating functional dyspepsia with antianxiety, characterized in that the soothing and relieving qi composition is made of the following medicinal raw materials in parts by weight: 25-35 parts of Magnolia officinalis, 25-35 parts of Chuanxiong, 25-35 parts of Cyperus rotundus, 25-35 parts of White Peony Root, 25-35 parts of Bupleurum Root, 25-35 parts of Citrus aurantium, 25-35 parts of Curcuma aromatica, 25-35 parts of Citrus citron, 25-35 parts of Aucklandia lappa, 25-35 parts of Tangerine peel, 20-30 parts of Licorice, 25-35 parts of Corydalis yanhusuo and 45-60 parts of Amaranthus chinensis;

[0010] Preferably, the liver-soothing and qi-relief composition is made of the following medicinal raw materials in the following parts by mass: 31.4 parts of Magnolia officinalis, 31.4 parts of Chuanxiong, 31.4 parts of Cyperus rotundus, 31.4 parts of White Peony Root, 31.4 parts of Bupleurum Root, 31.4 parts of Citrus aurantium, 31.4 parts of Curcuma aromatica, 31.4 parts of Citrus citrus hand, 31.4 parts of Aucklandia lappa, 31.4 parts of Tangerine peel, 23.55 parts of Licorice, 31.4 parts of Corydalis yanhusuo and 58.85 parts of Amaranthus grandiflora.

[0011] Furthermore, the dosage form of the liver-soothing and qi-regulating composition is any one of pills, granules, tablets, oral liquid or capsules.

[0012] Furthermore, the liver-soothing and gas-regulating composition is prepared according to the following method: the medicinal raw materials are crushed and passed through an 80-120 mesh sieve, and mixed to obtain the active pharmaceutical ingredient; pharmaceutical excipients are added to the active pharmaceutical ingredient and prepared into a clinically acceptable oral preparation.

[0013] Furthermore, the soothing liver and relieving qi composition is prepared according to the following method: 1 / 2 to 2 / 3 of each medicinal material raw material is crushed and passed through an 80-120 mesh sieve, and the coarse head and fine powder after screening are respectively reserved; the remaining medicinal material raw materials are crushed into coarse powder; the coarse powder and the coarse head are mixed, and an ethanol solution of 6 to 8 times the total weight of the coarse powder and the coarse head is added, and the mixture is immersed at a temperature of 40 to 60° C. for 30 to 90 minutes, and then a first reflux extraction is performed for 1 to 2 hours, and then an ethanol solution of 6 to 8 times the total weight of the coarse powder and the coarse head is added for a second reflux extraction for 1 to 2 hours. The extracts are combined, ethanol is recovered under reduced pressure, filtered, the residues are recovered, and the extracts are concentrated to extract I, wherein the concentration of the ethanol solution used in the extraction is 45-65%; the residues obtained after the extraction are decocted with water for 2-3 times, each time with an amount of water that is 6-10 times the amount of the residues, each time for 1-3 hours, the decoctions are combined, filtered, and the filtrate obtained is concentrated to extract II, extract I and extract II are combined, fine powder is added, and mixed to obtain a pharmaceutical active ingredient; pharmaceutical excipients are added to the pharmaceutical active ingredient to prepare it into a clinically acceptable preparation.

[0014] Furthermore, the liver-soothing and qi-regulating composition is prepared according to the following method: the medicinal raw materials are extracted by distillation to obtain a distilled water phase, a distilled oil phase and a medicinal residue; the medicinal residue is extracted by decocting in water to obtain a decoction, the decoction and the distilled water phase are combined to obtain an extract, the extract is concentrated into an extract, and the extract, the distilled oil phase and suitable excipients are prepared into a clinically acceptable oral dosage form.

[0015] Furthermore, the liver-soothing and qi-regulating composition is prepared according to the following method: the medicinal raw materials are extracted by distillation to obtain a distilled water phase, a distilled oil phase and medicinal residues; the medicinal residues are extracted by decocting in water to obtain a decoction, and the decoction and the distilled water phase are combined to obtain an extract; the distilled oil phase is included by an inclusion agent to obtain an inclusion powder or an inclusion solution; after concentrating the extract, it is prepared into a clinically acceptable oral dosage form with the inclusion powder or the inclusion solution and suitable excipients.

[0016] Furthermore, the method for extracting the medicinal residue by decoction in water is as follows: adding water 6 to 8 times the mass of the medicinal raw material for a first decoction extraction for 2 to 3 hours; adding water 6 to 8 times the mass of the medicinal raw material and adjusting the pH value to 7.0 to 7.5, and performing a second decoction extraction for 2 to 3 hours.

[0017] Furthermore, the distillation extraction adopts an intermittent distillation extraction method, and the intermittent distillation extraction is performed alternately by fierce fire distillation and micro-boiling distillation;

[0018] Preferably, the intermittent distillation extraction uses water or alcohol solution as the extraction solvent; the total extraction time is 1 to 8 hours; the extraction process of the intermittent distillation extraction is cyclically carried out in a manner of first 10 to 20 minutes of high-fire distillation extraction and then 10 to 20 minutes of micro-boiling distillation extraction.

[0019] Furthermore, the inclusion agent is hydroxypropyl-β-cyclodextrin; the inclusion treatment method is: take 3 to 5 times the mass of the distilled oil phase of the inclusion agent, dissolve it, and then add the distilled oil phase at a speed of 1 to 2 ml / min under stirring conditions of 40 to 60 rpm, stir for 1.5 to 2.5 hours after the addition is completed, to obtain an inclusion solution; concentrate and dry until the moisture content is less than 5.0%, and then crush it through an 80 to 100 mesh sieve to obtain an inclusion powder.

[0020] The present invention provides a liver-soothing and gas-regulating composition, the principle and beneficial effects of which are:

[0021] Through animal experiments and clinical experiments, the inventors found that the Shugan Shunqi composition has the effect of treating anxiety, especially functional dyspepsia accompanied by anti-anxiety symptoms. In addition, the preparation of the active ingredients of the drug has a certain influence on the anti-anxiety effect of the drug. The inventors further developed ways to improve the effect of the Shugan Shunqi composition in treating anxiety, from crude drug powder preparations, to crude drug ethanol extract preparations, to crude drug distillation and decoction extraction preparations, step by step to improve the effect of the drug. Extracting the volatile oil components of the medicinal materials and adding them to the finished medicine by appropriate inclusion, and controlling the pH value during the decoction and extraction process can further improve the efficacy of the drug in treating anxiety.

[0022] Anxiety and depression are two common but different mental health conditions. Although they often occur in the same individual at the same time and have some overlap in symptoms, they are significantly different in clinical manifestations, pathogenesis, and treatment methods. In terms of clinical manifestations, anxiety disorders are mainly manifested as worries, fears, nervousness, and excessive attention to potential threats about the future. They may be accompanied by physical symptoms such as palpitations, rapid heartbeats, sweating, tremors, muscle tension, headaches, and stomach discomfort. Patients may experience sleep disorders, such as difficulty falling asleep or frequent awakenings. They may manifest as motor restlessness such as fidgeting, pacing, or rubbing hands and feet. Depression is mainly manifested by persistent low mood, loss of interest and happiness, and decreased self-worth. Thinking may become slow, lack motivation, and lose interest in daily activities. Excessive sleep or insomnia, changes in appetite, weight fluctuations, fatigue, or lack of energy may occur. Patients with depression may have suicidal thoughts or behaviors. The diagnostic criteria and reference scales of the two diseases are different, so it is very important and necessary to develop new treatment approaches and drugs for the two different mental illnesses. This technical solution is particularly aimed at studying anxiety disorders, and it is found that the liver-soothing and qi-smoothing composition has a good therapeutic effect on anxiety disorders. DETAILED DESCRIPTION

[0023] The specific embodiments listed in the present invention are only examples of the present invention, and the present invention is not limited to the specific embodiments described below. For those skilled in the art, any equivalent modifications and substitutions made to the embodiments described below are also within the scope of the present invention. Therefore, the equalization and modification made without departing from the spirit and scope of the present invention should be included in the scope of the present invention.

[0024] In the examples, if the specific conditions are not specified, the conditions are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for all reagents or instruments, they are all conventional products that can be purchased commercially. In order to better illustrate the present invention, numerous specific details are provided in the specific embodiments below. It should be understood by those skilled in the art that the present invention can be implemented equally without certain specific details. In other embodiments, methods, means, equipment and steps well known to those skilled in the art are not described in detail to highlight the gist of the present invention.

[0025] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art. Unless otherwise specified, the units used in this specification are all international standard units, and the numerical values ​​and numerical ranges appearing in the present invention should be understood to include the inevitable systematic errors in industrial production.

[0026] The specific formula of the liver-soothing and qi-regulating composition is as follows:

[0027] 25-35 parts of Magnolia officinalis, 25-35 parts of Chuanxiong, 25-35 parts of Cyperus rotundus (vinegar-processed), 25-35 parts of white peony root, 25-35 parts of Bupleurum root, 25-35 parts of Immature Citrus aurantium (fried), 25-35 parts of Curcuma, 25-35 parts of Citrus hand, 25-35 parts of Aucklandia lappa, 25-35 parts of Tangerine peel, 20-30 parts of Licorice, 25-35 parts of Corydalis (vinegar-fried), 45-60 parts of Amaranthus (Wedelia). This technical solution is mainly studied for drug use, and the formula composition is not adjusted. For the convenience of experimental research, the subsequent experimental content uniformly adopts a consistent formula, specifically referring to the formula in the embodiment. The above formula and value range can be used to achieve the therapeutic effect on depression.

[0028] Example 1

[0029] This embodiment provides a method for preparing a Shugan Shunqi preparation, which prepares the medicinal raw materials into pills with reference to the existing Shugan Shunqi pill standards. Specifically, the medicinal raw materials are:

[0030] 31.4 parts of Magnolia officinalis, 31.4 parts of Chuanxiong, 31.4 parts of Cyperus rotundus (vinegar-processed), 31.4 parts of White Peony Root, 31.4 parts of Bupleurum Root, 31.4 parts of Fructus Aurantii Immaturus (fried), 31.4 parts of Curcuma Radix, 31.4 parts of Citrus Palmito, 31.4 parts of Aucklandiae Radix, 31.4 parts of Tangerine Peel, 23.55 parts of Licorice, 31.4 parts of Corydalis (vinegar-processed), and 58.85 parts of Amaranthus;

[0031] The preparation method is as follows:

[0032] S1-1: Take each medicinal material according to the above weight proportions, grind each medicinal material and pass it through a 100-mesh sieve (a 80-120-mesh sieve can be used in actual operation), mix them evenly, and obtain the active ingredient of the medicine;

[0033] S1-2: Add an appropriate amount of adhesive (the adhesive is starch paste) to the active ingredient of the drug to prepare it into a water pill. Water pills are conventional dosage forms in the prior art and are prepared by conventional means, which will not be described in detail here. The preparation method refers to the method for preparing a liver-soothing and qi-soothing preparation described in the applicant's prior patent CN101461925B, and can be found in process 1 of the patent. The process adopts a method of directly crushing the traditional Chinese medicine into fine powder to prepare the medicine.

[0034] Example 2

[0035] This embodiment provides a method for preparing a soothing liver and shunning qi preparation. The medicinal materials are the same as those in Example 1. The preparation method is as follows: It is prepared by referring to process 2 in the specification of patent CN101461925B.

[0036] S2-1: Take thirteen medicinal materials according to the above weight portions and set aside;

[0037] S2-2: 2 / 3 weight portion (1 / 2 to 2 / 3 weight portion can be used in actual operation) of each medicinal material is taken, crushed and passed through a 100-mesh sieve (80 to 120 mesh sieve can be used in actual operation), and the coarse powder and fine powder after sieving are set aside separately;

[0038] S2-3: taking the remaining 1 / 3 of the raw medicinal materials by weight and crushing them into coarse powder;

[0039] S2-4: the coarse powder and the coarse head are mixed, an ethanol solution of 7 times the total weight of the coarse powder and the coarse head is added (6 to 8 times can be selected in actual operation), and the mixture is immersed at a temperature of 50° C. (40 to 60° C. can be selected in actual operation) for 60 min (30 to 90 min can be selected in actual operation), followed by a first reflux extraction for 2 hours (1 to 2 hours can be selected in actual operation), and then an ethanol solution of 7 times the total weight of the coarse powder and the coarse head is added (6 to 8 times can be selected in actual operation) for a second reflux extraction for 2 hours (1 to 2 hours can be selected in actual operation), the extracts are combined, ethanol is recovered under reduced pressure, filtered, the residue is recovered, and the extract is concentrated into extract I, wherein the volume fraction of the ethanol solution used in the extraction is 50% (45 to 65% can be selected in actual operation);

[0040] S2-5: decoct the residue obtained after extraction with water for 2 to 3 times (2 times can be used in actual operation), with the amount of water added each time being 6 to 10 times the amount of the residue (8 times can be used in actual operation), each time for 1 to 3 hours (1.5 hours can be used in actual operation), combine the decoctions, filter, concentrate the filtrate to extract II with half the weight of the residue, combine extract I and extract II, add the fine powder obtained in step S2-2, mix well, and obtain the active ingredient of the medicine;

[0041] S2-6: Add pharmaceutical excipients to the active pharmaceutical ingredient to prepare it into a clinically acceptable preparation. In this embodiment, the active pharmaceutical ingredient is specifically prepared into a water pill, that is, the binder is water. The preparation type and preparation method are conventional methods in the prior art and will not be described in detail here.

[0042] Example 3

[0043] This embodiment provides a method for preparing a soothing liver and shunning qi preparation. The medicinal materials are the same as those in Example 1. The general preparation process is as follows:

[0044] With reference to the drug composition of Example 1, take 13 medicinal pieces of Magnolia officinalis, Chuanxiong, Cyperus rotundus (vinegar-processed), White Peony Root, Bupleurum Root, Immature Citrus Aurantium (fried), Curcuma Radix, Citrus Foetida, Aucklandia Root, Tangerine Peel, Licorice, Corydalis (vinegar-fried), and Amaranthus chinensis, add volatile oil extractor, add 8 to 10 times of water (preferably 8 times of water) of medicinal material mass, intermittent distillation extraction for 1 to 8 hours, (preferably 3 to 6 hours, further preferably 6 hours), obtain distilled water phase, distilled oil phase and medicinal residues after extraction, then separate the distilled water phase, distilled oil phase and medicinal residues, and the distilled water phase is sieved through 200 mesh for standby use. Wherein, the specific operation mode of intermittent distillation extraction is: fierce fire distillation extraction for 10 to 20 minutes (preferably 10 minutes), adjust the heat to control the distillation system to be in a micro-boiling state for 10 to 20 minutes (preferably 10 minutes), and circulate according to the above program until the extraction process ends. The existing technology generally uses steam heating, and the heating power is controlled by controlling the steam pressure of the distillation equipment. High heat means that the heating steam pressure is controlled within the range of 0.04 to 0.06 MPa in actual operation, and slight boiling heating (low heat heating) means that the steam pressure is controlled within the range of 0.01 to 0.02 MPa.

[0045] After the intermittent distillation extraction is completed, the medicinal residue is decocted in water for two more times. The first time, the amount of water added is 6 to 8 times the weight of the medicinal material (preferably 7 times), and the decocting time is 2 to 3 hours (preferably 3 hours). The second time, the amount of water added is 6 to 8 times the weight of the medicinal material (preferably 7 times), and the decocting time is 2 to 3 hours (preferably 3 hours). Each time the decocting is performed, the medicinal liquid is passed through a 160-200 mesh sieve (preferably a 200 mesh sieve), and the distilled water phase and the two decoctions are combined for later use (hereinafter referred to as the extract).

[0046] The extract and distilled oil phase are used to make various preparations. Among them, the distilled oil phase needs to be encapsulated with an inclusion agent; the extract needs to be concentrated and dried. The above are all common steps in the preparation process.

[0047] The method of using an inclusion agent to carry out inclusion treatment on the distilled oil phase is as follows: take 3 to 5 times the mass of hydroxypropyl-β-cyclodextrin of volatile oil, dissolve it in 3 to 5 times the mass of water of hydroxypropyl-β-cyclodextrin; under stirring conditions of 40 to 60 rpm, add volatile oil at a speed of 1 to 2 ml / min, stir for 1.5 to 2.5 hours after the addition is completed, and obtain an inclusion compound solution; concentrate and dry until the water content is less than 5.0%, and then crush through an 80 to 100 mesh sieve to obtain an inclusion compound powder. Preferably, the inclusion agent is hydroxypropyl-β-cyclodextrin.

[0048] The specific process of extract concentration and drying is as follows: the extract is concentrated into a clear paste with a relative density of 1.20-1.25, and then a dry paste is obtained by drying, and the dry paste rate is 24%-27%; the dry paste is crushed and passed through an 80-100 mesh sieve to obtain ointment powder.

[0049] The specific preparation method is:

[0050] S3-1: Take 13 medicinal pieces of Magnolia officinalis, Chuanxiong, Cyperus rotundus (vinegar-processed), White Peony Root, Bupleurum Root, Citrus aurantium (fried), Curcuma Radix, Citrus Foetida, Aucklandia Root, Tangerine Peel, Licorice, Corydalis Root (vinegar-fried), and Amaranthus chinensis, add them into a volatile oil extractor, add 8 times the weight of the medicinal materials, and perform intermittent distillation extraction for 6 hours. After extraction, three parts of distilled water phase, distilled oil phase, and medicinal residue are obtained, and then the distilled water phase, distilled oil phase, and medicinal residue are separated, and the distilled water phase is passed through a 200-mesh sieve for standby use. Among them, the specific operation method of intermittent distillation extraction is: distillation extraction with high heat for 10 minutes, reducing the heat and slightly boiling for 10 minutes, and repeating according to the above procedure until the extraction process is completed.

[0051] S3-2: After the intermittent distillation extraction is completed, the medicinal residue is decocted in water for two more times. The first time, the amount of water added is 7 times the weight of the medicinal material, and the decoction is carried out for 3 hours. The second time, the amount of water added is 7 times the weight of the medicinal material, and the decoction is carried out for 3 hours. Each time the decoction is performed, the medicinal liquid is passed through a 200-mesh sieve, and the distilled water phase and the two decoction liquids are combined to obtain the extract for use.

[0052] S3-3: Preparation of inclusion compound powder of distilled oil phase: Take 4 times the mass of hydroxypropyl-β-cyclodextrin of distilled oil phase, dissolve it in water of 4 times the mass of hydroxypropyl-β-cyclodextrin, add the distilled oil phase dropwise at a rate of 1-2 ml / min under stirring at 50 rpm, stir for 2 hours after the addition is completed to obtain inclusion compound solution, dry the inclusion compound solution to a moisture content of less than 5.0%, and then pulverize it through an 80-mesh sieve to obtain inclusion compound powder;

[0053] S3-4: The extract is subjected to conventional concentration and drying treatment. First, the extract is concentrated to an extract with a relative density of 1.20 to 1.25 (30 to 70°C, measured by a Pomeranian pycnometer). The concentrated material is then dried to obtain a dry paste, which is crushed with a water-cooled grinder and sieved through an 80-mesh sieve for later use to obtain an ointment powder.

[0054] More specifically, the process of preparing the dry paste can be carried out by the following method:

[0055] Take the extract and start the single-effect concentrator, with the vacuum degree ≤-0.09Mpa, the temperature ≤75°C, and the steam pressure ≤0.30Mpa. Filter the extract through a bag filter with a mesh size of 250 and transfer it into the single-effect concentrator to concentrate it to a relative density of 1.20-1.25 (30-70°C, measured by a Pomeranian specific gravity meter). Then, the extract flows into the belt dryer at a speed of 200kg / h. The heating temperature of the first section of the belt dryer is set at 90-100°C; the heating temperature of the second section is set at 70-80°C; the heating temperature of the third section is set at 50-60°C. The dry paste after drying in the third section is collected, and the dry paste rate is 24%-27%.

[0056] S3-5: Granulation: Take the inclusion powder, ointment powder, cross-linked polyvinylpyrrolidone, microcrystalline cellulose and pregelatinized starch, mix and granulate them, and then mix and tablet them with magnesium stearate after granulation to obtain liver-soothing and qi-relieving tablets. The auxiliary materials and dosage ranges used in the preparation of tablets are: 4 to 8 parts of cross-linked polyvinylpyrrolidone (6 parts in the specific experiment), 10 to 20 parts of microcrystalline cellulose (15 parts in the specific experiment), and 0.75 to 1.5 parts of magnesium stearate (1.35 parts in the specific experiment). In the dry granulation step, pregelatinized starch is used, which is only used as a filling material. Pregelatinized starch is added according to the weight of other materials in the actual preparation process to ensure the established total amount of materials.

[0057] Correspondingly, based on this embodiment, those skilled in the art can also select appropriate preparation excipients and prepare them together with inclusion compound powder (or inclusion compound solution), extract, etc. according to the needs of dosage form selection, and prepare them into tablets, granules, capsules, oral liquids, etc., which will not be repeated here. The main components for achieving the drug effect are the active pharmaceutical ingredients including inclusion compound powder and ointment powder, and these active pharmaceutical ingredients can be prepared into various dosage forms according to specific needs and in the conventional manner of the prior art.

[0058] Example 4

[0059] This embodiment provides a preparation method of a soothing liver and shunning qi preparation. The medicinal materials are the same as those in Example 3. The difference between the preparation method and Example 3 is that:

[0060] After the intermittent distillation extraction is completed, the residue is decocted in water for two more times. The amount of water added for the first time is 6 to 8 times the weight of the medicinal material (preferably 7 times), and the decoction is performed for 2 to 3 hours (preferably 3 hours). The amount of water added for the second time is 6 to 8 times the weight of the medicinal material (preferably 7 times). During the second decoction, the pH value of the system consisting of the residue and water is adjusted to 7.0 to 7.5 (preferably 7.2) with sodium hydroxide, and the decoction is performed for 2 to 3 hours (preferably 3 hours). Each time the decoction is performed, the medicinal liquid is passed through a 160 to 200 mesh sieve (preferably a 200 mesh sieve), and the distilled water phase and the two decoction liquids are combined for standby use (hereinafter referred to as the extract).

[0061] More specifically, step S3-2 further includes: during the second decoction, the pH value of the system consisting of the residue and water is adjusted to 7.2 with sodium hydroxide, and then decocted for 3 hours.

[0062] The remaining steps are the same as those in Example 3.

[0063] Test Example 1

[0064] This experimental example is an anti-anxiety / depression animal experiment, as follows:

[0065] (1) Experimental animals and groups

[0066] This experiment used SD rats (SPF grade, weight 160-200g) as experimental animals, both male and female. After one week of adaptive feeding, the rats were randomly divided into 11 groups, namely: blank control group, anxiety model group, anxiety medication group 1, anxiety medication group 2, anxiety medication group 3, anxiety medication group 4; depression model group, depression medication group 1, depression medication group 2, depression medication group 3, depression medication group 4, among which, there were 16 blank control groups (including 8 for depression control and 8 for anxiety control), and 8 in each of the remaining groups. The blank control group did not receive any treatment and was free to drink water and eat.

[0067] Depression modeling: The modeling methods of depression model group, depression drug administration group 1, depression drug administration group 2, depression drug administration group 3, and depression drug administration group 4 are as follows: the depression model was established by CUMS method stimulation for 5 weeks, and the stress stimulation methods included: 1) fasting and water deprivation for 24 hours; 2) plantar electrical stimulation, 3) wet bedding; 4) tilting the mouse cage 45°; 5) behavioral restraint; 6) continuous shaking of the mouse cage; 7) olfactory stimulation; one of the above seven methods was randomly selected to stimulate the target rats every day, and the stimulation method was not repeated in two consecutive days.

[0068] Anxiety disorder modeling: The modeling methods of the anxiety disorder model group, anxiety disorder drug administration group 1, anxiety disorder drug administration group 2, anxiety disorder drug administration group 3, and anxiety disorder drug administration group 4 are as follows: the anxiety rat model was established by the empty bottle drinking water stimulation method, and uncertain empty bottle stimulation was performed during the modeling period. The modeling period was 21 days, and the rats were free to eat and drink during the modeling period.

[0069] (2) Dosage regimen

[0070] Blank control group: normal feeding, no medication;

[0071] Anxiety disorder model group: Model was established and the mice were gavaged with an equal amount of normal saline;

[0072] Anxiety disorder administration group 1: intragastric administration of the drug prepared in Example 1, dissolved in physiological saline;

[0073] Anxiety disorder medication group 2: intragastric administration of the drug prepared in Example 2, dissolved in physiological saline;

[0074] Anxiety disorder administration group 3: intragastric administration of the drug prepared in Example 3, dissolved in physiological saline;

[0075] Anxiety disorder administration group 4: intragastric administration of the drug prepared in Example 4, dissolved in physiological saline;

[0076] Depression model group: Modeling, intragastric administration of equal volume of saline;

[0077] Depression medication group 1: intragastric administration of the drug prepared in Example 1, dissolved in physiological saline;

[0078] Depression medication group 2: intragastric administration of the drug prepared in Example 2, dissolved in physiological saline;

[0079] Depression medication group 3: intragastric administration of the drug prepared in Example 3, dissolved in physiological saline;

[0080] Depression medication group 4: intragastric administration of the drug prepared in Example 4, dissolved in physiological saline;

[0081] Dosage design: Based on the usage and dosage recorded in the instructions of the marketed product - Shugan Shunqi Pills, the equivalent dose for rats was calculated to be 1.33g crude drug / kg, and the drug was administered according to this dose.

[0082] Dosage cycle: Administer once daily by gavage for 14 consecutive days.

[0083] (3) Experimental observations and results on depression

[0084] Effects of each group of drugs on the results of forced swimming test

[0085] After the last administration, the forced swimming test was performed: the rats in each experimental group were placed in a cylindrical glass container with a water depth of about 20 cm, so that the rats' limbs could not touch the bottom of the container, and the experimental water temperature of each group was kept consistent. The experimental rats were forced to swim for 6 minutes, and the total immobility time of the rats in each group after 4 minutes was recorded. The immobility time was defined as: the rats floated quietly in the water, without struggling or climbing the wall except for keeping their heads above the water. The experimental results are shown in Table 1.

[0086] Effects of each group of drugs on the sugar water preference results of rats

[0087] After the last administration, the rats in each group were subjected to a sugar water preference test. Before the experiment, sugar water training was first carried out. The method was: give each cage of rats two bottles of 1% sucrose solution to adapt to it for 24 hours, and replace the 1% sucrose solution with a bottle of pure water on the second day. After the sugar water training, fast for 12 hours and conduct a sugar water preference test. The method was: the rats were housed in a single cage, given 1 bottle of 1% sucrose solution and 1 bottle of pure water, and tested for 24 hours. To avoid position preference, the positions of the two bottles of water were exchanged every 12 hours. After the experiment, the respective consumption of 1% sucrose solution and pure water was recorded. The experimental results were calculated as follows: The formula for calculating sugar water preference is: Sugar water preference rate (%) = [sucrose solution consumption / (sucrose solution consumption + pure water consumption)] × 100%. The experimental results are shown in Table 1.

[0088] Effects of each group of drugs on the results of the rat tail suspension test

[0089] After the last administration, the tail suspension test was performed. During the experiment, the tail of each group of rats was fixed by 1 / 3, so that the head was suspended downward, and the immobility time of the rats was recorded. The immobility time was defined as: the body was vertically inverted, the four paws were clenched, and the tail suspension time was proportional to the degree of depression of the rats. The experimental results are shown in Table 1.

[0090] Table 1: Effects of each group of drugs on the forced swimming test, sugar water preference and tail suspension test of rats (x-±SD)

[0091]

[0092] Compared with the blank control group, # p<0.05, ## p<0.01; compared with the model group, * P<0.05, ** P<0.01, compared with depression medication group 3, △ p<0.05, △△ p<0.01;

[0093] From the above experimental results, we can know that:

[0094] The liver-soothing and qi-soothing composition for treating depression provided by the present invention can play an effective antidepressant effect, whether it is a direct powder preparation of crude drugs (Example 1), or a preparation of alcohol extraction of some medicinal materials (Example 2), or a combined preparation of volatile oil extracted from all medicinal materials by steam distillation (Examples 3 and 4). Among them, Example 2 extracts the medicinal materials by alcohol, and the obtained active pharmaceutical ingredients have a certain advantage over the effect of powdering crude drugs for the treatment of depression, while Examples 3 and 4 further make full use of the volatile oil components in the medicinal materials, and further improve the efficacy on the basis of Example 2.

[0095] At the same time, on the basis of Example 3, Example 4 of the present invention further improves the content of magnolol in the extract and the finished drug by adjusting the pH value of the system consisting of the drug residue and water to 7.2 with sodium hydroxide during the second decoction during the decoction of the drug residue after volatile oil extraction. After testing, at the same concentration level, during the preparation process of Example 4, the content of magnolol in the extract obtained after the extract was concentrated can reach 0.92 mg / g, which is greatly improved relative to the magnolol content of 0.71 mg / g in the embodiment. Therefore, it is speculated that during the second decoction of the drug residue, controlling the pH to be weakly alkaline is conducive to the dissolution of some effective ingredients in the drug residue, thereby further improving the efficacy.

[0096] In general, the original efficacy of the Shugan Shunqi composition is mainly to treat diseases such as indigestion. This technical solution has deeply developed the function of the combination and found that it also has ideal technical effects in the treatment of depression. Moreover, according to the specific implementation method of this test example, the modeling method of the experimental rats is completely unrelated to functional dyspepsia, gastrointestinal motility disorders, etc. This shows that the Shugan Shunqi composition can be used to treat symptoms unrelated to digestive system-related diseases, and the original use of the Shugan Shunqi composition has no relevance and technical inspiration for this new use. The Shugan Shunqi composition can play a role in the treatment of depression, which completely exceeds the expectations of those skilled in the art. On this basis, the inventor further developed ways to improve the effect of the Shugan Shunqi composition in treating depression, from crude drug powder preparations, to crude drug ethanol extract preparations, and then to crude drug distillation and decoction extraction preparations, which step by step improved the drug effect.

[0097] Effects of each group of drugs on the results of open field test in rats

[0098] After the last administration, an open field test was performed. The open field test was conducted in an open field test box with a height of 40 cm and a bottom area of ​​100 cm × 100 cm. In a quiet environment, the rats were placed in the central square of the open field test box. After they adapted for 3 minutes, the experiment began. The total movement path length and immobility time of each group of rats within 5 minutes were recorded. The experimental results are shown in Table 2.

[0099] Table 2: Effects of each group of drugs on the results of open field test in rats (x-±SD)

[0100] Total movement path (cm) Exercise time(s) Blank control group 174.25±24.55 254.21±32.84 Depression model group <![CDATA[105.78±23.42 ## ]]> <![CDATA[142.96±31.03 ## ]]> Depression medication group 1 <![CDATA[133.91±31.57 * ]]> <![CDATA[183.31±25.84 * ]]> Depression medication group 2 <![CDATA[146.23±19.85 * ]]> <![CDATA[205.46±24.19 * ]]> Depression medication group 3 <![CDATA[165.01±18.72 ** ]]> <![CDATA[231.15±21.30 ** ]]> Depression medication group 4 <![CDATA[171.29±24.07 **△ ]]> <![CDATA[242.35±28.61 **△ ]]>

[0101] Compared with the blank control group, # p<0.05, ## p<0.01; compared with the model group, * P<0.05, ** P<0.01, compared with depression medication group 3, △ p<0.05, △△ p<0.01;

[0102] From the above experimental results, it can be seen that the soothing liver and shunning qi composition for treating depression provided by the present invention, each group of drugs can have an effective antidepressant effect. At the same time, based on Example 3, the depression medication group 4 corresponding to Example 4 of the present invention has further improvement in the total movement path compared with the depression medication group 3.

[0103] (4) Anxiety disorder experimental observation and results: Effects of each group of drugs on the elevated plus maze experimental behavior of rats (anxiety disorder)

[0104] After the last administration, the elevated plus maze test was performed to evaluate the effects of each group of drugs on the results of the elevated plus maze test of rats. The performance of each group of rats within 5 minutes was recorded, including:

[0105] 1) the number of entries into the open arm (OE) and time (OT);

[0106] 2) the number of entries into the closed arm (CE) and time (CT);

[0107] According to the above data, the percentage of open arm entry times (OE%) and the percentage of open arm residence time (OT%) were calculated. The experimental results are shown in Table 3:

[0108] Table 3: Effects of each group of drugs on elevated plus maze behavior (x-±SD)

[0109]

[0110] Compared with the blank control group, # p<0.05, ## p<0.01; compared with the model group, * P<0.05, ** P<0.01, compared with anxiety medication group 3, △ p<0.05, △△ p<0.01;

[0111] It can be seen from the above experimental results that each group of drugs provided by the present invention can play an effective anti-anxiety effect. At the same time, based on Example 3, the anxiety medication group 4 has further improved OE% and OT% compared with the depression medication group 3. The original efficacy of the Shugan Shunqi composition is mainly to treat diseases such as dyspepsia, and there is no report on its efficacy in treating anxiety. According to the specific implementation method of this test example, the modeling method of the experimental rat (anxiety symptoms) is completely unrelated to functional dyspepsia, gastrointestinal motility disorders, etc. This shows that the action pathway and mechanism of the Shugan Shunqi composition for treating anxiety are not significantly related to digestive system-related diseases, and the original use of the Shugan Shunqi composition has no association and technical inspiration for this new use. It is very likely that the Shugan Shunqi composition is different from the mechanism of action of treating functional dyspepsia, gastrointestinal motility disorders, etc., to achieve the treatment of nervous system diseases such as anxiety. On this basis, the inventor further developed a way to improve the effect of the Shugan Shunqi composition in treating depression, from the crude drug powder preparation, to the crude drug ethanol extract preparation, and then to the crude drug distillation and decoction extraction preparation, step by step to improve the drug effect.

[0112] Test Example 2

[0113] A clinical trial was conducted to evaluate the efficacy and safety of Shugan Shunqi Pills in the treatment of patients with functional dyspepsia accompanied by anxiety or depression symptoms and liver depression and qi stagnation syndrome. The approved Shugan Shunqi Large Honey Pills were used as the drug of administration.

[0114] Case selection

[0115] 1) Diagnostic criteria:

[0116] (1) The diagnosis of traditional Chinese and Western medicine was formulated in accordance with the technical guidelines for clinical research on new Chinese medicines for functional dyspepsia (FD) issued by the Center for Drug Evaluation of the State Food and Drug Administration. The main symptoms of liver depression and qi stagnation syndrome are fullness and discomfort in the stomach or pain in the stomach; secondary symptoms are fullness in the flanks; irritability; heartburn or noisy feeling; frequent belching; sighing; attacks or aggravations due to emotional distress; pale red tongue, thin white fur, and stringy pulse. The diagnosis can be made by referring to the tongue and pulse if at least one of the main symptoms is present and any two of the secondary symptoms are present.

[0117] (2) Diagnosis of associated mood disorders:

[0118] A score of ≥5 on the Generalized Anxiety Scale (GAD-7) can be diagnosed as accompanied by anxiety symptoms;

[0119] A score of ≥5 on the PHQ-9 depression screening scale can be diagnosed as having depressive symptoms.

[0120] 2) Inclusion criteria: meeting the above diagnostic criteria;

[0121] For patients with anxiety symptoms, the score of Generalized Anxiety Scale (GAD-7) is ≥5 points and <19 points;

[0122] Those with depressive symptoms had a PHQ-9 depression screening scale score of ≥5 and <19 points;

[0123] Aged 18 to 70 years old, regardless of gender; voluntarily participate in clinical trials, give informed consent and sign the informed consent form; approved by the ethics committee of the hospital where they are located.

[0124] 3) Exclusion criteria include:

[0125] Those who do not meet the diagnostic criteria of Western medicine or traditional Chinese medicine; 13 C or 14 C. Patients whose breath test results show that HP is positive; indigestion caused by organic diseases of the digestive system, such as peptic ulcer, Barrett's esophagitis, erosive gastritis (grade 2 or above), moderate to severe atrophic gastritis (pathology is moderate to severe atrophy, moderate to severe intestinal metaplasia, dysplasia), digestive tract tumors, digestive tract bleeding, hepatobiliary and pancreatic diseases, intestinal obstruction, inflammatory bowel disease, etc.; systemic diseases that affect digestive tract motility, such as diabetes, chronic renal insufficiency, connective tissue disease, nervous system lesions, etc.; patients with serious primary heart, brain, liver, lung, kidney, blood or serious diseases that affect their survival; patients with a history of abdominal surgery (except appendectomy and cesarean section); pregnant and lactating women, and those who have plans to have children in the near future; the blind, deaf, and dumb , intellectual disabilities, mental disorders and other physical disabilities; suspected or confirmed history of alcohol or drug abuse; those who have participated in other drug clinical trials in the past 3 months, or are taking drugs that may affect the effectiveness evaluation of the trial drugs (such as non-steroidal anti-inflammatory drugs, anticholinergic drugs, glucocorticoids, antidepressants, etc.); allergic constitution, such as a history of allergies to two or more drugs or foods, or known allergies to the ingredients of this drug; a history of liver and kidney dysfunction; other diseases that, according to the judgment of the researchers, reduce the possibility of inclusion or complicate inclusion, such as frequent changes in work environment, which are prone to loss to follow-up; patients diagnosed with major depression or severe anxiety and depression, and other people who are not suitable for participating in this study according to the judgment of the researchers.

[0126] 4) Exit criteria: patients who fail to take medication as prescribed, the dosage is less than 80% of the prescribed amount or exceeds 120% of the prescribed amount; patients who have adverse reactions and are not suitable to continue taking medication; patients whose condition worsens and affects their work or study; patients who have certain comorbidities, complications or special physiological changes and are not suitable to continue the trial; patients who use prohibited drugs specified in the protocol; patients who withdraw from the trial midway, or patients who do not explicitly request to withdraw from the trial but no longer accept medication and testing and are lost to follow-up.

[0127] 5) Exclusion criteria: those who did not meet the inclusion criteria and were mistakenly included; those who met the inclusion criteria but never took medication after inclusion, or those who had no follow-up records; those who used combined medications outside the prescribed range, especially those that had a significant effect on the trial drugs, affecting the effectiveness and safety judgment; those who violated the medication plan and used other Chinese and Western medicines for treatment.

[0128] 6) Termination criteria: serious safety issues occur during the trial; the trial finds that the drug treatment effect is too poor or even ineffective and has no clinical value; the drug marketing authorization holder requests termination (such as due to funding reasons, management reasons, etc.).

[0129] Clinical Data

[0130] A total of 50 patients with FD (functional dyspepsia) (33 with anxiety and 17 with depression) were selected as the research subjects, including 22 males and 28 females; age (46.90±12.08) years old; height (162.02±7.25) cm; weight (56.40±10.43) kg; TCM syndrome score (9.38±3.43) points; anxiety symptom score (6.12±3.34) points; depression symptom score (4.76±3.37) points.

[0131] Treatment

[0132] 1) Give the patient Shugan Shunqi Pills (National Medicine Standard No. Z20026802, manufacturer: Chongqing Xi'an Pharmaceutical Co., Ltd.) for oral administration, 9 grams (1 bag) at a time, 3 times a day, before breakfast, lunch and dinner.

[0133] The treatment course is 4 weeks. During the trial, the subjects should pay attention to a light diet, avoid smoking, drinking, spicy, cold, and greasy food; avoid emotional excitement and sulking.

[0134] 2) Combined medication and treatment

[0135] (1) During the trial, it is prohibited to use other drugs and treatments related to the treatment of this disease, including antacids, H2 receptor blockers, proton pump inhibitors, gastrokinetic drugs, antidepressants, calcium ion blockers, beta-blockers, anticholinesterase drugs, anticonvulsants, opioids, 5-HT4 receptor agonists, dopamine D2 receptor antagonists, non-steroidal anti-inflammatory drugs and macrolide antibiotics, as well as other Chinese and Western medicines that are clearly marked in the instructions as being able to affect the symptoms of functional dyspepsia and improve anxiety and depression symptoms. Treatments include but are not limited to acupuncture, massage, physical therapy, etc.

[0136] (2) The name of the medication (or other treatment name), dosage, frequency of use, and time of use of medications that must be continued for concurrent diseases or other treatments must be recorded in the research medical records. During the trial, the original type of medication, usage, and dosage should be kept unchanged as much as possible to facilitate analysis and reporting in the summary.

[0137] (3) If adverse events occur in the subjects during the trial, corresponding drugs may be used for treatment. However, the researchers need to evaluate whether the drugs used have an impact on the efficacy or safety evaluation of the trial drugs, and determine whether the subjects need to withdraw from the trial as appropriate.

[0138] (4) After the clinical trial is completed, patients who have not recovered should be treated according to current clinical routine methods.

[0139] Observation indicators

[0140] The patients' FD symptom scores, TCM syndrome scores, anxiety symptom scores, depression symptom scores, safety indicators, vital signs, and adverse events were recorded at the first visit and after treatment.

[0141] 1) FD symptom score: The subjects were scored according to their FD symptoms (0-2-4-6 points).

[0142] 2) TCM syndrome scoring: Each major symptom and secondary symptom of the subject was scored separately.

[0143] 3) Anxiety symptom score: The Generalized Anxiety Scale (GAD-7) was used for self-assessment.

[0144] 4) Depression symptom score: The Health Questionnaire-9 Depression Symptom Cluster Scale (PHQ-9) was used for self-assessment.

[0145] 5) Safety evaluation: the occurrence and severity of adverse reactions and adverse events. Changes in basic physical indicators such as heart rate, respiration, blood pressure, and body temperature.

[0146] Efficacy evaluation criteria

[0147] 1) Criteria for judging the efficacy of single FD symptoms:

[0148] Markedly effective: the original symptoms disappeared. Effective: the original symptoms were reduced by 2 levels. Improved: the original symptoms were reduced by 1 level. Ineffective: the original symptoms did not improve or worsened.

[0149] 2) FD efficacy evaluation criteria:

[0150] Cured: symptoms disappear. Significantly effective: symptom improvement rate ≥ 80%. Improved: symptom improvement rate ≥ 50%. Ineffective: symptoms do not improve significantly, or even worsen, symptom improvement rate < 50%.

[0151] Improvement rate = [(improvement) / total number of cases] × 100%; marked effectiveness rate = [(marked effect) / total number of cases] × 100%; cure rate = [(cure) / total number of cases] × 100%; total effectiveness rate = [(cure + marked effect + improvement) / total number of cases] × 100%.

[0152] 3) Criteria for determining the efficacy of TCM syndromes:

[0153] Clinical cure: TCM symptoms and signs disappear or basically disappear, and the syndrome score decreases by ≥95%. Marked effect: TCM symptoms and signs are significantly improved, and the syndrome score decreases by ≥70%. Effective: TCM symptoms and signs are improved, and the syndrome score decreases by ≥30%. Ineffective: TCM symptoms have no significant improvement, or even worsen, and the syndrome score decreases by <30%. Effective rate = [(effective) / total number of cases] × 100%; Marked effect = [(marked effect) / total number of cases] × 100%; Cure rate = [(cured) / total number of cases] × 100%; Total effective rate = [(cured + marked effect + effective) / total number of cases] × 100%.

[0154] 4) Evaluation of the efficacy of anxiety and depression symptoms:

[0155] Cured: returned to normal level. Remarkable effect: the severity of symptoms decreased by two levels. Effective: the severity of symptoms decreased by 1 level. Ineffective: the severity of symptoms did not improve, or even worsened. Effective rate = [(cured + marked effect + effective) / total number of cases] × 100%; Remarkable effect = [(cured + marked effect) / total number of cases] × 100%; Cure rate = [(cured) / total number of cases] × 100%.

[0156] 5) Overall efficacy evaluation:

[0157] Cured: FD cured + anxiety or depression symptoms improved effectively. Remarkably effective: FD markedly effective + anxiety or depression symptoms improved effectively. Improved: FD improved + anxiety or depression symptoms improved effectively. Ineffective: FD ineffective + anxiety or depression symptoms improved ineffectively. Improvement rate = [(improvement) / total number of cases] × 100%; Remarkably effective = [(remarkably effective) / total number of cases] × 100%; Cured rate = [(cured) / total number of cases] × 100%; Total effective rate = [(cured + markedly effective + improved) / total number of cases] × 100%.

[0158] Statistical processing

[0159] SPSS 22.0 statistical software was used. Two-sided test was used. Measurement data that conformed to normal distribution were expressed as (x±s) and t test was used. Rank sum test was used for those that did not conform to normal distribution. Count data were expressed as frequency or percentage (%) and χ test was used. 2 P<0.05 was considered statistically significant.

[0160] Clinical trial results

[0161] The total number of clinical trials was 50, 46 of which were finally completed and 4 were withdrawn midway.

[0162] The efficacy of overall, FD, TCM symptoms, anxiety symptoms, and depression symptoms after treatment are shown in Tables 4 and 5.

[0163] Table 4: The efficacy of overall, FD, TCM symptoms, anxiety symptoms, and depression symptoms at the end of treatment (n, %)

[0164]

[0165] Table 5: FD single-item efficacy at the end of treatment (n, %)

[0166]

[0167] The experimental results showed that after treatment, the overall efficacy rate of patients, the total effective rate of FD, and the total effective rate of TCM syndrome efficacy were 60.87%, 63.04%, and 78.26%, respectively; the patients' anxiety and depression symptoms were significantly improved, with the total effective rates reaching 93.48% and 100%, respectively; the total effective rates of FD items such as postprandial fullness, early satiety, upper and middle abdominal pain, and burning sensation in the upper and middle abdomen were 58.70%, 86.96%, 73.91%, and 93.48%, respectively.

[0168] Comparison of FD symptoms, TCM syndromes, anxiety, depression symptoms self-rating scores and TCM single-item scores before and after treatment are shown in Tables 6 and 7. After treatment, the patients' FD symptoms, TCM syndromes, anxiety, depression symptoms self-rating scores and TCM single-item scores were all lower than those before treatment (all P < 0.05).

[0169] Table 6: Comparison of self-assessment scores of FD symptoms, TCM syndromes, anxiety and depression symptoms before and after treatment ( Compared with before treatment, * indicates P < 0.05)

[0170]

[0171] Table 7: Comparison of TCM single-item scores before and after treatment ( Compared with before treatment, * indicates P < 0.05)

[0172]

[0173] In summary, Shugan Shunqi Pills are safe and effective for functional dyspepsia accompanied by anxiety symptoms or depression symptoms (liver depression and qi stagnation syndrome), can improve patients' anxiety and depression symptoms and improve their quality of life, and are worthy of clinical promotion and application.

[0174] Test Example 3: Exploration of the preparation and processing methods of active pharmaceutical ingredients

[0175] (1) Exploration of intermittent distillation extraction

[0176] Study on the extraction process of distilled oil phase (preparation of distilled oil phase by intermittent distillation extraction):

[0177] The distilled oil phase extraction method of this experimental example was carried out in the manner of Example 3, except that the intermittent distillation extraction process was slightly changed, and 20 kg of medicinal materials were extracted (each medicinal material was prepared according to the formula ratio of Example 3).

[0178] Test 1: Distill and extract under high heat for 15 minutes, adjust the heat to keep the distillation system in a slightly boiling state for 15 minutes, and repeat the above procedure until the extraction process is completed, a total of 6 hours. 23.0 mL of distilled oil phase is obtained, which is a clear oil with a strong aroma of distilled oil phase.

[0179] Test 2: Distill and extract under high heat for 10 minutes, adjust the heat to keep the distillation system in a slightly boiling state for 10 minutes, and repeat the above procedure until the extraction process is completed, a total of 4 hours. 22.1 mL of distilled oil phase was obtained, which was a clear oil with a strong aroma of distilled oil phase.

[0180] Test 3: Distillation was carried out under high heat for 4 hours. 19.5 mL of distilled oil phase was obtained, which was an emulsified oil with a strong aroma of distilled oil phase.

[0181] Test 4: Distillation was performed at a low boiling temperature for 4 hours. 15.2 mL of distilled oil phase was obtained, which was a clear oil with a strong aroma of distilled oil phase.

[0182] In the process of distillation and extraction of medicinal materials, if fierce fire distillation is used throughout the process, the efficiency of obtaining the distilled oil phase is not ideal, and the properties of the obtained distilled oil phase are turbid and of poor quality. If the method of micro-boiling distillation is used throughout the process, although the obtained distilled oil phase is clear, the amount of distilled oil phase obtained is too small. It can be seen that whether the medicinal materials are continuously distilled and extracted under more intense extraction conditions or milder extraction conditions, the amount of distilled oil phase obtained is not ideal (not exceeding 20mL). Alternating between fierce fire distillation extraction and micro-boiling distillation extraction can effectively increase the extraction amount of the distilled oil phase, and adding the distilled oil phase to the finished drug product can further enhance its anti-anxiety and anti-depression effects.

[0183] Therefore, when preparing the liver-soothing and gas-soothing preparation, the preferred method of extracting the distilled oil phase is: using a distillation fire that is intermittently circulated for 10-20 minutes and a total distillation time of 3-6 hours. The inventors have also preliminarily analyzed the reasons why the above method can increase the amount of distilled oil phase obtained, which may be as follows: Slow fire is to boil out the volatile oil in the medicinal materials, which will float or partially dissolve in hot water. After a certain amount is accumulated, it is boiled with fierce fire, and the accumulated volatile oil is concentrated and distilled back to the collector for cooling and collection. If fierce fire boiling is always used, due to the large extractor, the amount of volatile oil is very small, and some volatile oil may stay on the wall of the extractor and is not easy to return to the collector, so the amount is relatively small. For a long time, fierce fire distillation may cause a compatibility reaction between the substances, resulting in turbidity of the volatile oil. Slow fire distillation is always used, and the distillation force is not enough, and it is not easy to distill and collect a large amount of volatile oil.

[0184] The experimental data of Test Example 1 show that the full utilization of volatile oils in medicinal materials has a significant effect on improving the therapeutic effect of drugs. How to further improve the amount and quality of volatile oils is the key to improving the therapeutic effect of the overall preparation. This test example studies the effect of distillation extraction on the amount and quality of volatile oils, creating conditions for improving the therapeutic effect of drugs.

[0185] (2) Exploration of pH value of decoction extraction

[0186] The preparation process of the extract (adjustment of pH value during the second decoction extraction) was studied in the following manner:

[0187] Test 1: Prepare the extract according to the optimal process of Example 4 of the present invention, wherein, during the second water decoction extraction, the pH value of the mixture of the dregs and water is adjusted to 7.2 to prepare the final extract, and after the extract is concentrated into an extract (60°C, density 1.30), the content of the monarch drug Magnolia officinalis (in terms of magnolol) in the extract, as well as the identification spots of costus root, citron, Corydalis yanhusuo, peony root, and liquorice are determined. The determination method refers to the quality standard of Shugan Shunqi Pills (WS-11169 (ZD-1169) -2002-2011Z) to detect costus root, citron, Corydalis yanhusuo, peony root, liquorice thin layer identification, and magnolol content.

[0188] The results of thin layer identification of costus root, citron, corydalis, peony root and liquorice showed that the control and test spots were clear; the content of magnolia bark phenol in the extract was 0.92mg / g. The experimental research found that before the second decoction extraction, the pH value of the extraction system was adjusted to 7.0-7.5, which could achieve an ideal extraction effect, and the content of magnolia bark phenol in the extract could reach more than 0.9mg / g.

[0189] Test 2: The extract was prepared according to Example 3 of the present invention. The difference between Example 3 and Example 4 is that during the second water decoction extraction, the pH value of the mixture of the residue and water was not adjusted, and the decoction extraction was performed directly. The experimental results showed that the control and test spots of costusroot and corydalis were clear, and the color was lighter than that of the extract prepared in "Test 1". The content of magnolol in the extract was 0.71 mg / g.

[0190] The above experimental results show that during the second decoction and extraction process, the pH value of the system composed of the drug residue and water can be controlled between 7.0-7.5 (for example, the pH of the second decoction and extraction is controlled to 7.2). This operation method is very effective in ensuring the transfer rate of costus root, citron, corydalis, peony, licorice and magnolia bark, and increasing the content of the effective ingredients of magnolia bark in the extract (i.e., the extract). In test 2, since the pH value of the system composed of the drug residue and water in the second decoction and extraction was not adjusted, the content of magnolia bark was reduced, and the spots for identification of costus root and corydalis were relatively weak, indicating that the extraction method directly affected the transfer rate of the effective ingredients in magnolia bark, costus root and corydalis.

[0191] The above experimental results show that in the stage of extract preparation, the pH value of the extraction system for the second decoction extraction needs to be adjusted to ensure the extraction rate of the effective ingredients. The content of the effective ingredients is one of the key technical points that affect the effect of the preparation. The inventors studied the effect of pH control on these effective ingredients during the water decoction extraction process, and further selected optimized conditions to improve the therapeutic effect of the preparation.

[0192] (3) Screening of inclusion agents

[0193] The preparation process of the inclusion compound powder (solution) is described in the best embodiment of Example 4. The types of inclusion agents were studied, and the effects of hydroxypropyl-β-cyclodextrin and β-cyclodextrin in preparing the inclusion compound were studied.

[0194] Scheme 1: Dissolve 4 times the mass of the distilled oil phase of hydroxypropyl-β-cyclodextrin in 4 times the mass of water, add the distilled oil phase at a rate of 1-2 ml / min under stirring at 50 rpm, stir for 2 hours after the addition is complete, and obtain the inclusion compound solution. After inclusion, it is a transparent viscous liquid, and after pulsating vacuum drying, it is a white flaky solid that is easy to break.

[0195] Scheme 2: Replace the hydroxypropyl-β-cyclodextrin in "Scheme 1" with β-cyclodextrin in equal amounts. β-cyclodextrin has poor solubility and the liquid after inclusion is a white paste. After standing, an oily substance floats on the upper layer. After pulsating vacuum drying, it becomes a white block solid.

[0196] The results of the study showed that hydroxypropyl-β-cyclodextrin has a better encapsulation / solubilization effect on the distilled oil phase of this product than β-cyclodextrin, so hydroxypropyl-β-cyclodextrin was selected to prepare the inclusion compound. The preparation of the inclusion compound will affect the compatibility of the distilled oil phase and the preparation as a whole, thereby affecting the therapeutic effect of the drug.

[0197] In summary, the composition of the present scheme has shown therapeutic effects on depression and anxiety in a variety of preparation methods, and has obtained unexpected technical effects relative to the prior art. In addition, the preparation process of the combination and the way of obtaining the active ingredients of the medicine will affect the effect of the drug treatment of depression and anxiety to a certain extent. This technical scheme has studied the way to improve the efficacy of the drug from the powdered preparation of crude drug, to the ethanol extract preparation of crude drug, and then to the distillation of crude drug and the decoction extraction preparation. It is found that the method of distilling crude drug and then decoction extraction preparation makes full use of volatile oils and other effective ingredients, and can obtain the most ideal therapeutic effect. In addition, the method of distilling crude drug and then decoction extraction preparation is adopted, the parameters of intermittent distillation extraction are controlled, the pH value of the second decoction extraction is controlled, and the inclusion agent of the distilled oil phase is selected, which plays a very critical role in improving the acquisition amount and quality of the key effective ingredient volatile oil, improving the extraction amount of the active ingredients of the medicinal materials, and the compatibility of the volatile oil and the preparation, further ensuring the effect of more optimized treatment of depression and anxiety, and the application effect is more significant.

[0198] The above is only an embodiment of the present invention, and the common knowledge such as the known specific technical solutions and / or characteristics in the solution is not described in detail here. It should be pointed out that for those skilled in the art, several modifications and improvements can be made without departing from the technical solution of the present invention, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicality of the patent. The scope of protection required by this application shall be based on the content of its claims, and the specific implementation methods and other records in the specification can be used to interpret the content of the claims.

Claims

1. Application of the liver-soothing and qi-regulating composition in the preparation of antianxiety drugs, It is characterized in that The soothing liver and relieving qi composition is prepared from the following medicinal raw materials in parts by weight: 25-35 parts of Magnolia officinalis, 25-35 parts of Chuanxiong, 25-35 parts of Cyperus rotundus, 25-35 parts of White Peony Root, 25-35 parts of Bupleurum Root, 25-35 parts of Citrus aurantium, 25-35 parts of Curcuma Radix, 25-35 parts of Citrus Hand, 25-35 parts of Aucklandia Root, 25-35 parts of Tangerine Peel, 20-30 parts of Licorice, 25-35 parts of Corydalis and 45-60 parts of Amaranthus; Preferably, the liver-soothing and qi-relief composition is made of the following medicinal raw materials in the following parts by mass: 31.4 parts of Magnolia officinalis, 31.4 parts of Chuanxiong, 31.4 parts of Cyperus rotundus, 31.4 parts of White Peony Root, 31.4 parts of Bupleurum Root, 31.4 parts of Citrus aurantium, 31.4 parts of Curcuma aromatica, 31.4 parts of Citrus citrus hand, 31.4 parts of Aucklandia lappa, 31.4 parts of Tangerine peel, 23.55 parts of Licorice, 31.4 parts of Corydalis yanhusuo and 58.85 parts of Amaranthus grandiflora.

2. Use of the liver-soothing and gas-smoothing composition in the preparation of drugs for improving, assisting in the treatment or treating functional dyspepsia associated with anxiety, It is characterized in that The soothing liver and relieving qi composition is prepared from the following medicinal raw materials in parts by weight: 25-35 parts of Magnolia officinalis, 25-35 parts of Chuanxiong, 25-35 parts of Cyperus rotundus, 25-35 parts of White Peony Root, 25-35 parts of Bupleurum Root, 25-35 parts of Citrus aurantium, 25-35 parts of Curcuma Radix, 25-35 parts of Citrus Hand, 25-35 parts of Aucklandia Root, 25-35 parts of Tangerine Peel, 20-30 parts of Licorice, 25-35 parts of Corydalis and 45-60 parts of Amaranthus; Preferably, the liver-soothing and qi-relief composition is made of the following medicinal raw materials in the following parts by mass: 31.4 parts of Magnolia officinalis, 31.4 parts of Chuanxiong, 31.4 parts of Cyperus rotundus, 31.4 parts of White Peony Root, 31.4 parts of Bupleurum Root, 31.4 parts of Citrus aurantium, 31.4 parts of Curcuma aromatica, 31.4 parts of Citrus citrus hand, 31.4 parts of Aucklandia lappa, 31.4 parts of Tangerine peel, 23.55 parts of Licorice, 31.4 parts of Corydalis yanhusuo and 58.85 parts of Amaranthus grandiflora.

3. The use according to any one of claims 1 or 2, Features: The dosage form of the liver-soothing and qi-regulating composition is any one of pills, granules, tablets, oral liquids or capsules.

4. The use according to any one of claims 1 or 2, Features: The soothing liver and relieving qi composition is prepared according to the following method: the medicinal raw materials are crushed and passed through a 80-120 mesh sieve, and mixed to obtain the active pharmaceutical ingredient; pharmaceutical excipients are added to the active pharmaceutical ingredient to prepare it into a clinically acceptable oral preparation.

5. Use of the soothing liver and sedating qi composition according to claim 1 in the preparation of antianxiety drugs, Features: The soothing liver and relieving qi composition is prepared according to the following method: 1 / 2 to 2 / 3 of the weight of each medicinal material is crushed and passed through an 80-120 mesh sieve, and the coarse and fine powders after screening are respectively reserved; the remaining medicinal materials are crushed into coarse powder; the coarse powder and the coarse head are mixed, and an ethanol solution of 6 to 8 times the total weight of the coarse powder and the coarse head is added, and the mixture is immersed at a temperature of 40 to 60° C. for 30 to 90 minutes, and then a first reflux extraction is performed for 1 to 2 hours, and then an ethanol solution of 6 to 8 times the total weight of the coarse powder and the coarse head is added. The second reflux extraction is performed for 1 to 2 hours, the extracts are combined, ethanol is recovered under reduced pressure, filtered, the residues are recovered, and the extract is concentrated into extract I, wherein the concentration of the ethanol solution used in the extraction is 45 to 65%; the residues obtained after the extraction are decocted with water for 2 to 3 times, each time the amount of water added is 6 to 10 times the amount of the residues, each time for 1 to 3 hours, the decoctions are combined, filtered, the filtrate obtained is concentrated into extract II, extract I and extract II are combined, and then fine powder is added and mixed to obtain the active ingredient of the drug; Pharmaceutical excipients are added to the active ingredients of the drug to prepare it into a clinically acceptable preparation.

6. Use of the soothing liver and relieving qi composition according to claim 1 in the preparation of antianxiety drugs, It is characterized in that The liver-soothing and qi-regulating composition is prepared according to the following method: the medicinal raw materials are extracted by distillation to obtain a distilled water phase, a distilled oil phase and medicinal residues; the medicinal residues are extracted by decocting in water to obtain a decoction, the decoction and the distilled water phase are combined to obtain an extract, the extract is concentrated into an extract, and the extract, the distilled oil phase and suitable excipients are prepared into a clinically acceptable oral dosage form.

7. Use of the soothing liver and relieving qi composition according to claim 1 in the preparation of antianxiety drugs, Features: The liver-soothing and gas-regulating composition is prepared according to the following method: the medicinal raw materials are extracted by distillation to obtain a distilled water phase, a distilled oil phase and medicinal residues; the medicinal residues are extracted by decocting in water to obtain a decoction, and the decoction and the distilled water phase are combined to obtain an extract; the distilled oil phase is subjected to inclusion treatment with an inclusion agent to obtain an inclusion compound powder or an inclusion compound solution; after concentrating the extract, it is prepared into a clinically acceptable oral dosage form with the inclusion compound powder or the inclusion compound solution and appropriate excipients.

8. Use of the liver-soothing and qi-regulating composition according to claim 6 or 7 in the preparation of antianxiety drugs, Features: The method for extracting the medicinal residue by decoction in water is as follows: adding water 6 to 8 times the mass of the medicinal raw material for a first decoction extraction for 2 to 3 hours; adding water 6 to 8 times the mass of the medicinal raw material and adjusting the pH value to 7.0 to 7.5, and performing a second decoction extraction for 2 to 3 hours.

9. Use of the liver-soothing and qi-regulating composition according to claim 6 or 7 in the preparation of antianxiety drugs, Features: The distillation extraction adopts an intermittent distillation extraction method, and the intermittent distillation extraction is carried out alternately by fierce fire distillation and micro-boiling distillation; Preferably, the intermittent distillation extraction uses water or alcohol solution as the extraction solvent; the total extraction time is 1 to 8 hours; the extraction process of the intermittent distillation extraction is cyclically carried out in a manner of first 10 to 20 minutes of high-fire distillation extraction and then 10 to 20 minutes of micro-boiling distillation extraction.

10. Use of the liver-soothing and qi-regulating composition according to claim 6 or 7 in the preparation of antianxiety drugs, Features: The inclusion agent is hydroxypropyl-β-cyclodextrin; the inclusion treatment method is: take 3 to 5 times the mass of the distilled oil phase of the inclusion agent, dissolve it, add the distilled oil phase at a speed of 1 to 2 ml / min under stirring conditions of 40 to 60 rpm, stir for 1.5 to 2.5 hours after the addition is completed, to obtain an inclusion solution; concentrate and dry until the water content is less than 5.0%, and then crush it through an 80 to 100 mesh sieve to obtain an inclusion powder.

Citation Information

Patent Citations

  • Medicament composition for treating hepatopathy and preparation method thereof

    CN101461925B

  • Novel pill for soothing liver and regulating qi

    CN101433694A

  • Medicament composition for treating hepatopathy and preparation method thereof

    CN101461925A

  • Method for extraction of Chinese medicine composite for liver disease

    CN101766786A

  • Preparation method of extract of traditional Chinese medicine with functions of regulating qi, relieving pain, invigorating stomach and promoting digestion

    CN103623296A